Table II.
Poisson regression for risk of contracting COVID-19 in patients with atopic dermatitis
| Factor | Crude IRR (95% CI) | P Value | Adjusted IRR (95% CI)∗ | P Value |
|---|---|---|---|---|
| AD vs no AD—main analysis | 1.41 (1.34-1.48) | <.0001 | 1.18 (1.12-1.24) | <.0001 |
| AD vs no AD—sensitivity analysis 1† | 1.51 (1.45-1.56) | <.0001 | 1.18 (1.12-1.24) | <.0001 |
| AD vs no AD—sensitivity analysis 2‡ | 1.33 (1.14-1.56) | <.0001 | 1.31 (1.11-1.53)§ | .001 |
| AD vs no AD—age subgroup analysis | ||||
| Age 20-40 y | 1.32 (1.18-1.47) | <.0001 | 1.18 (1.05-1.33) | .007 |
| Age ≥41 y | 1.44 (1.37-1.53) | <.0001 | 1.18 (1.12-1.25) | <.0001 |
| AD vs no AD—sex subgroup analysis | ||||
| Men | 1.36 (1.26-1.47) | <.0001 | 1.16 (1.07-1.25) | <.0001 |
| Women | 1.45 (1.36-1.54) | <.0001 | 1.20 (1.12-1.28) | <.0001 |
| Dupilumab vs no systemic medication | 0.62 (0.49-0.78) | <.0001 | 0.66 (0.52-0.83) | <.0001 |
| Methotrexate vs no systemic medication | 0.80 (0.54-1.17) | .25 | 0.82 (0.56-1.21) | .32 |
| Prednisone vs no systemic medication | 1.16 (1.04-1.30) | .007 | 1.13 (1.01-1.26) | .03 |
| Cyclosporine vs no systemic medication | 1.37 (0.96-1.94) | .08 | 1.20 (0.84-1.71) | .32 |
| Azathioprine vs no systemic medication | 1.68 (0.87-3.24) | .12 | 1.61 (0.83-3.10) | .16 |
| Dupilumab vs methotrexate | 0.78 (0.50-1.21) | .26 | 0.80 (0.51-1.27) | .35 |
| Dupilumab vs prednisone | 0.53 (0.42-0.68) | <.0001 | 0.58 (0.45-0.74) | <.0001 |
| Dupilumab vs cyclosporine | 0.45 (0.30-0.68) | <.0001 | 0.57 (0.36-0.90) | .02 |
| Dupilumab vs azathioprine | 0.37 (0.18-0.73) | .004 | 0.40 (0.20-0.82) | .01 |
AD, Atopic dermatitis; IRR, incidence rate ratio.
Adjusted for sex, age, race/ethnicity, payment type, and comorbidities (eg, asthma, rhinitis, overweight/obese, congestive heart failure, chronic ischemic heart disease, chronic kidney disease, chronic obstructive pulmonary disease, essential hypertension, human immunodeficiency virus, type 2 diabetes mellitus, and type 1 diabetes mellitus).
Sensitivity analysis 1 includes subjects with missing race or ethnicity, type of payment, and/or sex.
Sensitivity analysis 2 includes subjects aged 20-59 years with zip code in California or New York and excludes subjects with a history of asthma, rhinitis, overweight or obese, congestive heart failure, chronic ischemic heart disease, chronic kidney disease, chronic obstructive pulmonary disease, essential hypertension, human immunodeficiency virus, type 2 diabetes mellitus, and/or type 1 diabetes mellitus.
Adjusted for sex, age, race/ethnicity, payment type.